Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987295 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
A Phase 2 study, sponsored by Alector.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03987295 is a Phase 2 study that has completed, run by Alector. The registered enrollment target is 33 participants.
The verdict
NCT03987295, a Phase 2 study, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Interventions
- DRUG AL001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-09-27 |
| Est. Completion | 2024-06-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03987295
The ClinicalTrials.gov registry entry for NCT03987295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AL001 is the first listed.
NCT03987295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03987295 about?
NCT03987295 is a clinical study titled "A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)". A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
What is the current status of trial NCT03987295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-09-27. Estimated completion is 2024-06-05.
What interventions are being tested in trial NCT03987295?
The interventions under investigation include: AL001 (DRUG).
Who is sponsoring clinical trial NCT03987295?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.